BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 21, 2011
View Archived Issues
SPINK1 identified as potential therapeutic target in prostate cancer
Read More
GSK-3 inhibitor SC-001 may have potential for the treatment of Parkinson's disease
Read More
Neuroprotective efficacy hypothesized for Klotho enhancers
Read More
New dual DPP IV/AP-N inhibitors prepared by IMTM
Read More
Research Development Foundation patents novel urocortin-2 analogues
Read More
New B-raf inhibitors reported by Array BioPharma and Genentech
Read More
Lilly and Avid receive FDA complete response letter for Amyvid
Read More
Vardenafil plus tamsulosin improves LUTS in subjects with BPH in long-term study
Read More
CHMP recommends approval of Lucentis in new indication
Read More
Nerviano enters into oncology license agreement with Novartis
Read More
CHMP adopts negative opinion for Vectibix in combination with chemotherapy
Read More
Insys Therapeutics reports phase III data for fentanyl sublingual spray
Read More
Lonza and Athera sign development and manufacturing agreement for PC-mAb
Read More
Scientists at Anacor Pharmaceuticals prepare new antiprotozoal agents
Read More
Regeneron and sanofi-aventis begin phase II trial of MAb SAR-231893 in eosinophilic asthma
Read More
University of Pennsylvania designs novel adamantane analogues for influenza and related disorders
Read More
Euthymics Bioscience begins EB-1010 trial for major depression
Read More
KAI Pharmaceuticals begins enrollment of phase II study of KAI-4169 in secondary hyperparathyroidism
Read More
Polaris begins enrollment in phase II trial of ADI-PEG 20 in malignant mesothelioma
Read More
KineMed extends collaboration with Bristol-Myers Squibb for Alzheimer's disease
Read More
Genentech's pivotal trial of vismodegib in advanced basal cell carcinoma meets primary endpoint
Read More
CHMP adopts positive opinion regarding new birth control pill NOMAC/E2
Read More
Septodont acquires local anesthesia reversal agent OraVerse from Novalar
Read More
Quark terminates phase II study of PF-04523655 early, plans phase IIb study
Read More
Cell Therapeutics opens enrollment in pivotal PIX-R trial of pixantrone
Read More